Catalyst News and Research

RSS

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Regence acquires assets of Kinetix Living

As part of its continued focus on developing programs designed to meet employers' needs, Regence has acquired the assets of Kinetix Living Corp., a Seattle-based company that provides customized health and nutrition programs to corporate clients and individuals throughout the country.

11 Mar 2010

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

9 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Democrats now see a homestretch for health overhaul plan

President Barack Obama will take to the road next week for a push in America's heartland on health care reform.

4 Mar 2010

Palliative care helps improve quality, cut end of life care costs

The Philadelphia Inquirer reports on palliative care and focuses on a fairly typical American hospital in Abington.

1 Mar 2010

Ratifying global tobacco control treaty: Opportunity for U.S. to lead struggle against tobacco usage

The fifth anniversary of the international treaty to address the global tobacco epidemic presents a significant opportunity for President Obama to continue his strong leadership on tobacco control by submitting the treaty to the Senate for ratification and urging its quick approval.

1 Mar 2010

JBG to develop new facility for cancer research

The JBG Companies has been chosen by the General Services Administration to build and own a new facility to house the nation's premier center for cancer research, the National Cancer Institute (NCI) in Montgomery County, Maryland.

25 Feb 2010

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

Scientists create tiny RNA molecule to synthesize proteins

An extremely small RNA molecule created by a University of Colorado at Boulder team can catalyze a key reaction needed to synthesize proteins, the building blocks of life. The findings could be a substantial step toward understanding "the very origin of Earthly life," the lead researcher contends.

23 Feb 2010

University of Missouri researchers visualize "terminals" inside proline degrading enzyme

If subway terminals didn't exist and people had to exit subway stations to switch subway lines, transit time would increase. People also may encounter distractions, such as grabbing a cup of coffee, instead of getting on the other line. Molecules also use "terminals" to save transit time during enzyme-catalyzed processes. Using advanced X-radiation techniques, University of Missouri researchers were able to visualize one of these terminals inside of an enzyme that degrades proline, which is an amino acid that has a central role in metabolism.

19 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Scotland's $13 billion chemicals sector to showcase new initiatives at Informex

Scotland's $13 billion chemicals sector will showcase innovative new initiatives at Informex this week, highlighting the country's research and manufacturing expertise, and offering integrated, world-class solutions to the global chemicals industry.

17 Feb 2010

Smithsonian Institution joins Arizona State University in innovative education and science partnership

The Smithsonian Institution in Washington, D.C. has joined Arizona State University in an innovative education and science partnership aimed at sustaining a biodiverse planet. On Feb. 12, Secretary Wayne Clough, head of the Smithsonian, and ASU President Michael M. Crow launched a global classroom - with one foot in Arizona's Sonoran desert and the other in the tropical landscapes of Panama.

17 Feb 2010

Chemists adopt new approach to optimise enzyme for practical applications

Engineers are unlikely to tinker with the cooling system if they want to increase the size of an engine. Yet chemists at the Max Planck Institute for Coal Research have adopted an approach similar to this in their efforts to optimise an enzyme for practical applications. They

16 Feb 2010

Abbott acquires Belgium-based Solvay Pharmaceuticals for $6.2 billion

Abbott today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets.

16 Feb 2010

NorTech announces winners of annual Innovation Awards program

NorTech, in partnership with Crain's Cleveland Business, is pleased to announce the winners of its annual Innovation Awards program which honors the achievements of Northeast Ohio's most innovative organizations and leaders.

16 Feb 2010

p62 and ERK proteins lead to development of obesity and insulin resistance, say scientists

New research by University of Cincinnati scientists implicates a new protein in obesity development and highlights a protein pair's "team effort" in regulating obesity and insulin resistance.

15 Feb 2010

Gold nanoparticles for cancer treatment

World Gold Council (WGC) has today published 'Gold for Good: Gold and nanotechnology in the age of innovation', a research paper detailing new scientific and technological innovations using gold. The report, which was produced in conjunction with Cientifica Ltd, the world's leading source of global business and investor intelligence about nanotechnologies, demonstrates how gold nanoparticles offer the potential to overcome many of the serious issues facing mankind over the coming decades.

12 Feb 2010

Quebec transplantation: 431 people receive 499 organs from 138 deceased donors

Owing to the generosity of Quebecers, 499 organs from 138 deceased donors in 2009 were transplanted into 431 recipients. Though there were 13 fewer donors than in 2008, Québec posted an average of more than 3.6 transplanted organs per deceased donor in 2009, placing the province among the leaders in Canada and even North America. "We're particularly proud of the sustained collaboration of professionals in hospitals in 2009," says Louis Beaulieu, chief executive officer of Québec-Transplant, the organization responsible for coordinating the organ donation process.

11 Feb 2010

Catalyst News and Research

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Regence acquires assets of Kinetix Living

Viatronix V3D-Colon software used for the President's colon cancer screening exam

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

Democrats now see a homestretch for health overhaul plan

Palliative care helps improve quality, cut end of life care costs

Ratifying global tobacco control treaty: Opportunity for U.S. to lead struggle against tobacco usage

JBG to develop new facility for cancer research

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Scientists create tiny RNA molecule to synthesize proteins

University of Missouri researchers visualize "terminals" inside proline degrading enzyme

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Scotland's $13 billion chemicals sector to showcase new initiatives at Informex

Smithsonian Institution joins Arizona State University in innovative education and science partnership

Chemists adopt new approach to optimise enzyme for practical applications

Abbott acquires Belgium-based Solvay Pharmaceuticals for $6.2 billion

NorTech announces winners of annual Innovation Awards program

p62 and ERK proteins lead to development of obesity and insulin resistance, say scientists

Gold nanoparticles for cancer treatment

Quebec transplantation: 431 people receive 499 organs from 138 deceased donors

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News